Quality & complianceOfficial

Denmark flags Zyprexa 10 mg olanzapine injection supply problems linked to manufacturing issues

🇩🇰 DKMA · Mon 26 Oct 2026

The Danish Medicines Agency says Cheplapharm's Zyprexa 10 mg powder for solution for injection is affected by production problems, with disruption expected from October to the end of November 2026.

The Danish Medicines Agency (DKMA) has published a supply notice on Zyprexa 10 mg powder for solution for injection from Cheplapharm Registration GmbH. The notice, dated 26 October 2026, says there are current problems with the product's supply.

The medicine contains the active substance olanzapine (ATC code N05AH03). DKMA gives the cause of the disruption as production problems.

The expected period of supply difficulty runs from the start of October to the end of November 2026. The notice does not specify how severe the shortage is, which pack sizes are affected, or whether any alternatives are available.

DKMA directs enquiries about the current status to the company. The notice appears in the agency's section on medicine supply announcements, which also covers foreign alternatives that may be supplied when supply fails.

What it means for your team

  • Supply and QA teams handling olanzapine injectables in Denmark should check the DKMA notice and contact Cheplapharm for the latest status, as the agency refers status questions to the company.
  • The disruption window stated is October to end-November 2026; the notice gives no further detail on volumes or recovery, so contingency planning should allow for changes.
  • Because the stated cause is production problems, quality teams may wish to follow any further company communication, though the notice gives no information on the nature of the issue.
  • Market-access and pharmacy-facing teams should be aware that DKMA lists foreign alternatives for supply failures on its website, but the notice does not say whether any apply here.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →